RU2006124515A - СПОСОБ ПРОГНОЗИРОВАНИЯ ЭФФЕКТИВНОСТИ ИНТЕРФЕРИРУЮЩЕЙ РНК (PHKi) - Google Patents
СПОСОБ ПРОГНОЗИРОВАНИЯ ЭФФЕКТИВНОСТИ ИНТЕРФЕРИРУЮЩЕЙ РНК (PHKi) Download PDFInfo
- Publication number
- RU2006124515A RU2006124515A RU2006124515/13A RU2006124515A RU2006124515A RU 2006124515 A RU2006124515 A RU 2006124515A RU 2006124515/13 A RU2006124515/13 A RU 2006124515/13A RU 2006124515 A RU2006124515 A RU 2006124515A RU 2006124515 A RU2006124515 A RU 2006124515A
- Authority
- RU
- Russia
- Prior art keywords
- phki
- reagent
- reagents
- effectiveness
- target gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Data Mining & Analysis (AREA)
- Biophysics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Evolutionary Computation (AREA)
- Bioethics (AREA)
- Theoretical Computer Science (AREA)
- Software Systems (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
Claims (18)
1. Способ создания алгоритма для прогнозирования эффективности в отношении PHKi реагента для PHKi, заключающийся в том, что
а) экспериментально определяют эффективность в отношении PHKi множества реагентов для PHKi, которые содержат последовательность, комплементарную по меньшей мере одному гену-мишени; и
б) с помощью полученного набора данных осуществляют обучение искусственной нейронной сети.
2. Способ по п.1, в котором эффективность PHKi определяют, оценивая количество белка, кодируемого геном-мишенью.
3. Способ по п.1, в котором эффективность PHKi определяют с помощью анализа репортерного гена.
4. Способ по п.1, в котором мишенью реагента для PHKi является 3'-UTR слитой мРНК, кодирующей репортерный белок.
5. Способ по п.1, в котором данные, полученные при использовании различных слитых мРНК, могут быть нормализованы.
6. Способ по п.1, в котором определяют эффективность по меньшей мере 100 реагентов для PHKi, предпочтительно по меньшей мере 1000 реагентов для PHKi.
7. Способ по п.1, в котором последовательности реагентов для PHKi выбраны произвольно.
8. Способ по п.1, в котором последовательности реагентов для PHKi имеют область длиной от 15 до 30 нуклеотидов, в достаточной степени комплементарную для связывания с мРНК-мишенью.
9. Способ по п.1, в котором комплементарная область реагента для PHKi содержит одно или несколько ошибочных спариваний относительно соответствующей области гена-мишени.
10. Способ по п.1, в котором реагент для PHKi представляет собой siPHK.
11. Способ по п.1, в котором реагент для PHKi представляет собой shPHK.
12. Способ по п.1, в котором реагент для PHKi представляет собой miPHK.
13. Алгоритм, полученный с помощью способа по одному из предыдущих пунктов.
14. Машиночитаемый носитель данных, содержащий алгоритм по п.13.
15. Компьютерная система, содержащая алгоритм по п.13 и аппаратные средства компьютера.
16. Способ прогнозирования эффективности в отношении PHKi реагента для PHKi, заключающийся в том, что
а) рассматривают множество последовательностей реагентов для PHKi, которые содержат область, комплементарную конкретному гену-мишени;
б) в отношении указанных последовательностей реагентов для PHKi выполняют обученный алгоритм по п.13 с использованием нейронной сети; и
в) отбирают последовательность(-и) реагента(-ов) для PHKi, которые согласно прогнозу должны обладать эффективностью.
17. Способ ингибирования экспрессии конкретного гена-мишени, заключающийся в том, что
а) рассматривают множество последовательностей реагентов для PHKi, которые содержат область, комплементарную конкретному гену-мишени;
б) в отношении указанных последовательностей реагентов для PHKi выполняют обученный алгоритм по п.13 с использованием нейронной сети;
в) отбирают последовательность(-и) реагента(-ов) для PHKi, которые согласно прогнозу должны обладать эффективностью;
г) синтезируют реагент(-ы) для PHKi, отобранные на стадии (в); и
д) подвергают клетки, экспрессирующие ген-мишень, воздействию реагента(-ов) для PHKi, полученных на стадии (г).
18. Способ по п.16 или 17, в котором эффективности реагентов для PHKi, отобранных на стадии (в), превышают конкретное пороговое значение.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52843003P | 2003-12-10 | 2003-12-10 | |
| US60/528,430 | 2003-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006124515A true RU2006124515A (ru) | 2008-01-20 |
Family
ID=34699869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006124515/13A RU2006124515A (ru) | 2003-12-10 | 2004-12-09 | СПОСОБ ПРОГНОЗИРОВАНИЯ ЭФФЕКТИВНОСТИ ИНТЕРФЕРИРУЮЩЕЙ РНК (PHKi) |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1694843A1 (ru) |
| JP (1) | JP2007523632A (ru) |
| KR (1) | KR20060126499A (ru) |
| CN (1) | CN1890370A (ru) |
| AU (1) | AU2004298527A1 (ru) |
| BR (1) | BRPI0417489A (ru) |
| CA (1) | CA2545675A1 (ru) |
| RU (1) | RU2006124515A (ru) |
| WO (1) | WO2005059132A1 (ru) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006016365B4 (de) * | 2006-04-05 | 2015-08-13 | Qiagen Gmbh | RNA-Interferenz Tags |
| WO2008071771A2 (en) * | 2006-12-15 | 2008-06-19 | Novartis Ag | Inhibition of gpr4 |
| WO2008122314A1 (de) * | 2007-04-10 | 2008-10-16 | Qiagen Gmbh | Rna-interferenz tags |
| EP2260102A1 (en) | 2008-03-25 | 2010-12-15 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
| US20110311521A1 (en) | 2009-03-06 | 2011-12-22 | Pico Caroni | Novel therapy for anxiety |
| EP2241323A1 (en) | 2009-04-14 | 2010-10-20 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Tenascin-W and brain cancers |
| CN101625732B (zh) * | 2009-08-03 | 2011-11-30 | 杭州电子科技大学 | 江河潮水水位的预测方法 |
| EP2292266A1 (en) | 2009-08-27 | 2011-03-09 | Novartis Forschungsstiftung, Zweigniederlassung | Treating cancer by modulating copine III |
| WO2011036118A1 (en) | 2009-09-22 | 2011-03-31 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mex-3 |
| WO2011045352A2 (en) | 2009-10-15 | 2011-04-21 | Novartis Forschungsstiftung | Spleen tyrosine kinase and brain cancers |
| EP2542578A1 (en) | 2010-03-05 | 2013-01-09 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Smoc1, tenascin-c and brain cancers |
| US20130034543A1 (en) | 2010-04-19 | 2013-02-07 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear | Modulating xrn1 |
| EP2580239A1 (en) | 2010-06-10 | 2013-04-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mammalian sterile 20-like kinase 3 |
| WO2012168259A1 (en) | 2011-06-06 | 2012-12-13 | Novartis Forschungsstiftung, Zweigniederlassung | Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer |
| WO2013068431A1 (en) | 2011-11-08 | 2013-05-16 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
| CN103945850A (zh) | 2011-11-15 | 2014-07-23 | 诺华股份有限公司 | 磷酸肌醇-3-激酶抑制剂与Janus激酶2-信号转导和转录激活因子5通路的调节剂的组合 |
| US20140363448A1 (en) | 2012-01-02 | 2014-12-11 | Novartis Ag | Cdcp1 and breast cancer |
| US20150266961A1 (en) | 2012-03-29 | 2015-09-24 | Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute | Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer |
| US20150218238A1 (en) | 2012-06-29 | 2015-08-06 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear | Treating diseases by modulating a specific isoform of mkl1 |
| US20150184154A1 (en) | 2012-07-05 | 2015-07-02 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear | New treatment for neurodegenerative diseases |
| EP2869818A1 (en) | 2012-07-06 | 2015-05-13 | Novartis AG | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction |
| ES2761587T3 (es) | 2013-08-07 | 2020-05-20 | Friedrich Miescher Institute For Biomedical Res | Nuevo método de cribado para el tratamiento de la ataxia de Friedreich |
| US20170137824A1 (en) | 2014-06-13 | 2017-05-18 | Indranil BANERJEE | New treatment against influenza virus |
| US20170165261A1 (en) | 2014-07-01 | 2017-06-15 | Brian Arthur Hemmings | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
| WO2016046768A1 (en) | 2014-09-24 | 2016-03-31 | Friedrich Miescher Institute For Biomedical Research | Lats and breast cancer |
| WO2017072669A1 (en) | 2015-10-28 | 2017-05-04 | Friedrich Miescher Institute For Biomedical Research | Tenascin-w and biliary tract cancers |
| CN109360604B (zh) * | 2018-11-21 | 2021-09-24 | 南昌大学 | 一种卵巢癌分子分型预测系统 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0212302D0 (en) * | 2002-05-28 | 2002-07-10 | Isis Innovation | Method of selecting targets for gene silencing by RNA interference |
-
2004
- 2004-12-09 BR BRPI0417489-5A patent/BRPI0417489A/pt not_active IP Right Cessation
- 2004-12-09 EP EP04820427A patent/EP1694843A1/en not_active Withdrawn
- 2004-12-09 CA CA002545675A patent/CA2545675A1/en not_active Abandoned
- 2004-12-09 CN CNA2004800367195A patent/CN1890370A/zh active Pending
- 2004-12-09 RU RU2006124515/13A patent/RU2006124515A/ru not_active Application Discontinuation
- 2004-12-09 WO PCT/EP2004/014037 patent/WO2005059132A1/en active Application Filing
- 2004-12-09 AU AU2004298527A patent/AU2004298527A1/en not_active Abandoned
- 2004-12-09 JP JP2006543479A patent/JP2007523632A/ja active Pending
- 2004-12-09 KR KR1020067011510A patent/KR20060126499A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005059132A1 (en) | 2005-06-30 |
| EP1694843A1 (en) | 2006-08-30 |
| KR20060126499A (ko) | 2006-12-07 |
| CA2545675A1 (en) | 2005-06-30 |
| AU2004298527A1 (en) | 2005-06-30 |
| BRPI0417489A (pt) | 2007-05-22 |
| JP2007523632A (ja) | 2007-08-23 |
| CN1890370A (zh) | 2007-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006124515A (ru) | СПОСОБ ПРОГНОЗИРОВАНИЯ ЭФФЕКТИВНОСТИ ИНТЕРФЕРИРУЮЩЕЙ РНК (PHKi) | |
| Wen et al. | DeepMirTar: a deep-learning approach for predicting human miRNA targets | |
| Tafer et al. | RNAplex: a fast tool for RNA–RNA interaction search | |
| Schalamun et al. | Harnessing the MinION: An example of how to establish long‐read sequencing in a laboratory using challenging plant tissue from Eucalyptus pauciflora | |
| Guenzl et al. | Macro lncRNAs: a new layer of cis-regulatory information in the mammalian genome | |
| Chen et al. | A dynamic Bayesian network for identifying protein-binding footprints from single molecule-based sequencing data | |
| Karlik et al. | LncRNAs: genetic and epigenetic effects in plants | |
| Penny et al. | An overview of the introns-first theory | |
| Wang et al. | Gigantic genomes provide empirical tests of transposable element dynamics models | |
| DE60333032D1 (de) | Screening-verfahren zur identifizierung wirksamer prä-trans-spleissmoleküle | |
| Choquet et al. | Pre-mRNA splicing order is predetermined and maintains splicing fidelity across multi-intronic transcripts | |
| Nand et al. | Chromosome-scale assembly of the coral endosymbiont Symbiodinium microadriaticum genome provides insight into the unique biology of dinoflagellate chromosomes | |
| Devi et al. | Identification and validation of plant miRNA from NGS data—an experimental approach | |
| Gokhale et al. | A systems view of the protein expression process | |
| Morris | Ribosomal footprints on a transcriptome landscape | |
| CN106919809B (zh) | 一种响应逆境胁迫的lncRNAs二级结构功能注释方法 | |
| Li et al. | In vivo analysis of Caenorhabditis elegans noncoding RNA promoter motifs | |
| Hong Kong Biodiversity Genomics Consortium et al. | Chromosome-level genome assembly of the common chiton, Liolophura japonica (Lischke, 1873) | |
| Zhang et al. | Effects of elongation delay in transcription dynamics | |
| Jens | Dissecting Regulatory Interactions of RNA and Protein: Combining Computation and High-throughput Experiments in Systems Biology | |
| Marenduzzo et al. | A unified-field theory of genome organization and gene regulation | |
| Patton | The Dynamic Fate of the Exon Junction Complex | |
| Nielsen | The transcriptional landscape | |
| Rodrigues de Melo Costa | Genome-wide Determination Of Splicing Efficiency And Dynamics From RNA-Seq Data | |
| Hoppe | Understanding recursive splicing in the human genome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090602 |
|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090602 |
|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090602 |